{"id":68837,"date":"2026-06-24T23:51:24","date_gmt":"2026-06-24T15:51:24","guid":{"rendered":"https:\/\/flcube.com\/?p=68837"},"modified":"2026-06-24T23:51:27","modified_gmt":"2026-06-24T15:51:27","slug":"sanofis-wayrilz-rilzabrutinib-secures-japanese-approval-for-immune-thrombocytopenia-expanding-global-footprint-across-six-major-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68837","title":{"rendered":"Sanofi&#8217;s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sanofi S.A.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) announced that <strong>Japan&#8217;s Pharmaceuticals and Medical Devices Agency (PMDA)<\/strong> has approved <strong>Wayrilz (rilzabrutinib)<\/strong> for the treatment of <strong>persistent or chronic immune thrombocytopenia (ITP)<\/strong> in patients who demonstrate insufficient response to other therapies or experience problematic tolerability issues. This approval marks the sixth major regulatory authorization for Wayrilz, following previous approvals in the <strong>United States, European Union, United Arab Emirates, United Kingdom<\/strong>, and now <strong>Japan<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>PMDA (Japan)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full marketing approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Wayrilz (rilzabrutinib) \u2013 oral BTK inhibitor<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Persistent\/chronic ITP in refractory or intolerant patients<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>23 Jun 2026<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>Approved in US, EU, UAE, UK, and Japan<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Compound:<\/strong> <strong>Rilzabrutinib<\/strong> \u2013 novel oral reversible covalent Bruton&#8217;s tyrosine kinase inhibitor (BTKi)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First-in-class <strong>multi-immune modulation<\/strong> approach designed to restore immune balance rather than broad immunosuppression<\/li>\n\n\n\n<li><strong>Therapeutic Potential:<\/strong> Platform molecule with applicability across multiple rare immune-mediated and inflammatory diseases<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral dosing regimen offering improved convenience over injectable alternatives<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> Patients with persistent\/chronic ITP who have failed or cannot tolerate existing therapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-luna-3-phase-3-study-nct04562766\" class=\"wp-block-heading\">Clinical Evidence \u2013 LUNA 3 Phase 3 Study (NCT04562766)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Met<\/td><td>Statistically significant improvement in sustained platelet response<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Met<\/td><td>Positive impact on bleeding symptoms, quality of life measures, and durability of response<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable<\/td><td>Reversible covalent binding mechanism associated with reduced off-target effects<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Refractory\/intolerant ITP patients<\/td><td>Addresses critical unmet need in difficult-to-treat population<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The LUNA 3 study demonstrated that Wayrilz achieved both primary and secondary endpoints, showing clinically meaningful improvements in sustained platelet counts and reduction in bleeding-related symptoms compared to placebo.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-outlook\" class=\"wp-block-heading\">Market Impact &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ITP Treatment Landscape:<\/strong> Current options include corticosteroids, IVIG, splenectomy, and newer biologics, but many patients remain refractory or experience significant side effects<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> Japan represents the world&#8217;s third-largest pharmaceutical market with approximately 15,000-20,000 ITP patients, including an estimated 30-40% with refractory disease<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Wayrilz&#8217;s oral administration, favorable safety profile, and multi-immune modulation mechanism differentiate it from existing BTK inhibitors and biologic therapies<\/li>\n\n\n\n<li><strong>Platform Expansion:<\/strong> Success in ITP validates Sanofi&#8217;s reversible covalent BTK inhibition platform for potential expansion into other immune-mediated conditions including pemphigus, lupus, and inflammatory arthritis<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial performance, market adoption, and pipeline expansion. Actual results may differ due to risks including competitive dynamics, pricing pressures, reimbursement challenges, and clinical development outcomes for additional indications.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi S.A. (NASDAQ: SNY) announced that Japan&#8217;s Pharmaceuticals and Medical Devices Agency (PMDA) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68838,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[867,15,24,147],"class_list":["post-68837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-nasdaq-sny","tag-product-approvals","tag-rare-orphan-disease-drugs","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi&#039;s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi S.A. (NASDAQ: SNY) announced that Japan&#039;s Pharmaceuticals and Medical Devices Agency (PMDA) has approved Wayrilz (rilzabrutinib) for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who demonstrate insufficient response to other therapies or experience problematic tolerability issues. This approval marks the sixth major regulatory authorization for Wayrilz, following previous approvals in the United States, European Union, United Arab Emirates, United Kingdom, and now Japan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68837\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi&#039;s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets\" \/>\n<meta property=\"og:description\" content=\"Sanofi S.A. (NASDAQ: SNY) announced that Japan&#039;s Pharmaceuticals and Medical Devices Agency (PMDA) has approved Wayrilz (rilzabrutinib) for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who demonstrate insufficient response to other therapies or experience problematic tolerability issues. This approval marks the sixth major regulatory authorization for Wayrilz, following previous approvals in the United States, European Union, United Arab Emirates, United Kingdom, and now Japan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68837\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-24T15:51:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-24T15:51:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2401.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68837#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68837\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi&#8217;s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets\",\"datePublished\":\"2026-06-24T15:51:24+00:00\",\"dateModified\":\"2026-06-24T15:51:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68837\"},\"wordCount\":422,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68837#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2401.webp\",\"keywords\":[\"NASDAQ: SNY\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68837#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68837\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68837\",\"name\":\"Sanofi's Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68837#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68837#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2401.webp\",\"datePublished\":\"2026-06-24T15:51:24+00:00\",\"dateModified\":\"2026-06-24T15:51:27+00:00\",\"description\":\"Sanofi S.A. (NASDAQ: SNY) announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved Wayrilz (rilzabrutinib) for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who demonstrate insufficient response to other therapies or experience problematic tolerability issues. This approval marks the sixth major regulatory authorization for Wayrilz, following previous approvals in the United States, European Union, United Arab Emirates, United Kingdom, and now Japan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68837#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68837\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68837#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2401.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2401.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi's Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68837#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi&#8217;s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi's Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi S.A. (NASDAQ: SNY) announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved Wayrilz (rilzabrutinib) for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who demonstrate insufficient response to other therapies or experience problematic tolerability issues. This approval marks the sixth major regulatory authorization for Wayrilz, following previous approvals in the United States, European Union, United Arab Emirates, United Kingdom, and now Japan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68837","og_locale":"en_US","og_type":"article","og_title":"Sanofi's Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets","og_description":"Sanofi S.A. (NASDAQ: SNY) announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved Wayrilz (rilzabrutinib) for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who demonstrate insufficient response to other therapies or experience problematic tolerability issues. This approval marks the sixth major regulatory authorization for Wayrilz, following previous approvals in the United States, European Union, United Arab Emirates, United Kingdom, and now Japan.","og_url":"https:\/\/flcube.com\/?p=68837","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-24T15:51:24+00:00","article_modified_time":"2026-06-24T15:51:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2401.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68837#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68837"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi&#8217;s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets","datePublished":"2026-06-24T15:51:24+00:00","dateModified":"2026-06-24T15:51:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68837"},"wordCount":422,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68837#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2401.webp","keywords":["NASDAQ: SNY","Product approvals","Rare \/ orphan disease drugs","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68837#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68837","url":"https:\/\/flcube.com\/?p=68837","name":"Sanofi's Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68837#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68837#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2401.webp","datePublished":"2026-06-24T15:51:24+00:00","dateModified":"2026-06-24T15:51:27+00:00","description":"Sanofi S.A. (NASDAQ: SNY) announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved Wayrilz (rilzabrutinib) for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who demonstrate insufficient response to other therapies or experience problematic tolerability issues. This approval marks the sixth major regulatory authorization for Wayrilz, following previous approvals in the United States, European Union, United Arab Emirates, United Kingdom, and now Japan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68837#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68837"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68837#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2401.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2401.webp","width":1080,"height":608,"caption":"Sanofi's Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68837#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi&#8217;s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia \u2013 Expanding Global Footprint Across Six Major Markets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2401.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68837"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68837\/revisions"}],"predecessor-version":[{"id":68839,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68837\/revisions\/68839"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68838"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}